Chronic Obstructive Pulmonary Disease Sector Reviewed by GBI Research in Topical Study Available at MarketPublishers.com09 Feb 2016 • by Natalie Aster
LONDON – Persistent breathing problems and repeated exacerbations of the symptoms make chronic obstructive pulmonary disease (COPD) one of the primary causes of morbidity and the 5th-leading cause of death worldwide.
In spite of the inflow of novel therapies over the last years, there remain a number of unmet needs in the chronic obstructive pulmonary disease (COPD) market. Although there are manifold therapeutic options in the management of the disease, the presently available medications are merely aimed at managing the symptoms related to COPD, reducing the severity and frequency of COPD exacerbations and enhancing overall quality of life among the patients. To date, none of the available therapies have been shown to modify long-run development of the disease. There is hence a strong need for a disease modifying therapies (DMTs) that target the clinical course of the disease. The bulk of the unmet needs pertaining to COPD have also been related to poor adherence to medical therapy among patients owing to tedious drug delivery processes and the necessity of taking frequent daily doses, eventually resulting in poor compliance and symptomatic treatment.
Consequently, the focus of attention of the current drug development programmes lies in the development of once-daily, long-acting treatment by pharmacos seeking to benefit from surging patient demands. Multiple once-daily therapies have been already approved in the recent past.
Topical market study “Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation” elaborated by GBI Research provides an exhaustive analysis of the COPD market on a global scale.
The report covers the current clinical and commercial landscape, including a comprehensive review of the disease (epidemiology, etiology, symptoms, pathophysiology, diagnosis, evaluation of disease severity, treatment, treatment algorithms, prognosis), and a detailed overview of the marketed products. It presents an assessment of the molecule types and molecular targets in the pipeline, comprising the well-established ones and also new, first-in-class therapies. The study investigates the first-in-class products’ clinical potential based on their alignment to the pathways causing the disease. It gives an overview of the key trends in licensing deals and co-development deals relating to COPD products. The research publication casts light on the COPD market composition with respect to the leading molecule targets and types, limelighting the current unmet needs as well as discussing how they are likely to be addressed.
Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation
Published: December, 2015
Price: US$ 6,995.00
More reports by the publisher can be found at GBI Research page.